SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Droxinostat

Item No. 23869

CAS Registry No.:	99873-43-5
Formal Name:	4-(4-chloro-2-methylphenoxy)-N-hydroxy-butanamide
Synonym:	NS 41080
MF:	$C_{11}H_{14}ClNO_3$
FW:	243.7
Purity:	≥98%
UV/Vis.:	λ_{max}: 231, 281 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Droxinostat is supplied as a crystalline solid. A stock solution may be made by dissolving the droxinostat in the solvent of choice. Droxinostat is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of droxinostat in these solvents is approximately 30 mg/ml.

Droxinostat is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, droxinostat should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Droxinostat has a solubility of approximately 0.05 mg/ml in a 1:20 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Droxinostat is an inhibitor of histone deacetylase (HDAC) 3, 6, and 8 (IC_{50}s = 16.9, 2.47, and 1.46 µM, respectively).[1] It is selective for HDAC3, 6, and 8 over HDAC1, 2, 7, 9, and 10 (IC_{50}s = >20 µM). Droxinostat increases histone H3 and H4 acetylation in PPC-1 prostate, OVCAR3 ovarian, U937 leukemia, HT-29 colon, and T47D breast cancer cells. It also inhibits proliferation and colony formation of SMMC-7721 and HepG2 hepatocellular carcinoma cell lines *via* activation of mitochondrial apoptosis and reduction of cellular FLICE-inhibitory protein (c-FLIP).[2]

References

1. Wood, T.E., Dalili, S., Simpson, C.D., *et al.* Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. *Mol. Cancer Ther.* **9(1)**, 246-256 (2010).
2. Liu, J., Li, G., Wang, X., *et al.* Droxinostat, a histone deacetylase inhibitor, induces apoptosis in hepatocellular carcinoma cell lines *via* activation of the mitochondrial pathway and downregulation of FLIP. *Transl. Oncol.* **9(1)**, 70-78 (2016).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM